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Summary
The rs3129882, a noncoding variant in HLA-DR, was
found to be associated with Parkinson’s disease (PD)
using several genome-wide association studies. The aim
of this replication study was to explore the relationship
between this variant and PD in Iranian population.
Genomic DNA was extracted from peripheral blood
samples, and the rs3129882 SNP was genotyped using a
PCR-RFLP method in 520 PD patients and 520 healthy
Iranian controls. Significant differences were found in
allele frequencies between patients and controls (v2 =
4.64, P = 0.031). Under additive and dominant models,
the association of the SNP with PD risk is significant,
where the A allele was observed to be protective. The
results suggest that rs3129882 polymorphism may be a
risk factor for PD in Iranian. This is the first study
reporting such an association in this population. More
replication studies are needed to confirm this data.
Introduction
Parkinson’s disease (PD; OMIM 168600) is a progres-
sive neurodegenerative disorder, which impairs the
patient’s movement abilities. PD is estimated to affect
about 1–2% of the population over the age of
65 years (Darvish et al., 2013a,b; Emamalizadeh
et al., 2014). Based on existent knowledge, PD is
caused by numerous environmental and genetic fac-
tors, which underlie the loss of nigral dopaminergic
neurons (Schapira & Jenner, 2011; Welzel & Walsh,
2011). To date, at least 13 single genes contributing to
mendelian forms of PD have been detected (Lesage &
Brice, 2009). However, susceptibility variants are
mainly involved in sporadic form of PD, and several
risk factors have been identified via genome-wide asso-
ciation studies to be associated with the disease Pihl-
strom et al. (2013). Single nucleotide polymorphisms
(SNPs) such as rs823128, rs11248051 and rs3129882
has identified as risk factors for the disease (Simon-
Sanchez et al., 2009; Hamza et al., 2010; Chang
et al., 2011). The latest one, which is an SNP within
Human Leucocyte Antigens (HLA) region, was subject
of various association studies among different popula-
tions. A recent publication was a study performed on
Caucasian populations. In this investigation rs3129882
(A/G), a noncoding variant located in intron 1 of
HLA-DRA, was shown to be strongly associated with
sporadic PD (Hamza et al., 2010).
In this study, we carried out a replication study on
Iranian patients and controls to determine the associa-
tion between this variant and sporadic PD.
Materials and methods
Subjects
This study was performed on a total of 1040 subjects
comprising 520 unrelated Iranian patients and 520
healthy controls. The mean age of patients was
59.5  14.5 years and was composed of 278 men and
242 women (male:female ratio, 1.14:1). The two
groups had no significant differences in distributions
of age and gender. Besides, two studied groups were
adjusted for the ethnic origin and area of residences.
The diagnostic criteria for PD were based upon the
UK Parkinson’s disease Society Brain Bank Clinical
Diagnostic Criteria, and the disease was diagnosed by
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a neurologist. Controls were individuals free of PD or
a related movement disorder at the time of examina-
tion. Informed consent was obtained from all patients
and family members who participated in the study.
The study was approved by the ethic committee at
Shahid Beheshti University of Medical Sciences,
Tehran, Iran.
Genetic analysis
Genomic DNA was extracted from peripheral blood
samples following a standard salting out protocol
(Miller et al., 1988). The rs3129882 variant in intron 1
of HLA-DRA was genotyped through a polymerase
chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) method as previously described
(Chiang et al., 2012). Primers sequence and the enzyme
recognition site were as follows: 50AGATAAAAGGT
GGAATTGCCAAGGT30 (forward primer), 50CACTG
TTTACATTTTAGAGTCAGAAGCTTTT30 (reverse
primer) and GAANNNNTTC (PdmI). The underlines
in the reverse primer sequence and PdmI recognition
site indicate the mismatch nucleotide and polymorphic
site, respectively. The PCR was performed in a reaction
containing 150 ng genomic DNA, 0.3 mM of each pri-
mer, 0.2 mM dNTPs, 2.0 mM MgCl2 and 0.6 U Taq
polymerase. The PCR profile consisted of 95°C for
5 min followed by 35 cycles of 95°C for 45 s, 60°C for
45 s and 72°C for 40 s and a final extension step of
72°C for 5 min. The Products were digested with the
PdmI (Thermo Scientific, Vilnius, Lithuania) and sepa-
rated on a 3.0% agarose gel (allele A, 210-bp fragment;
allele G, 183- and 27-bp fragments). The accuracy of
the genotyping method was confirmed by the Sanger
sequencing of number of PCR fragments (15 AA, 15
AG and 15 GG).
Statistical analysis
Fisher’s exact test was used to confirm the Hardy–
Weinberg equilibrium (HWE) of rs3129882 in both
cases and controls. Pearson’s v2-tests were applied to
test for significance indifferences of genotype and allele
frequencies between two groups. We also examined
the association of rs3129882 (A/G) with the risk of
PD, under three models (additive (G/G = 0, G/A = 1
and A/A = 2), dominant (A/A and G/A vs. G/G) and
recessive (G/G and G/A vs. A/A)) using SNPassoc
package of R version 3.0.1 (http://www.Rproject.org)
Gonzalez et al. (2007). All other data were also analy-
sed using R version 3.0.1. Odds ratio together with
95% confidence interval (CI) was estimated, and a
P < 0.05 was considered as the statistically significant
degree.
Results
The rs3129882 (A/G) polymorphism was examined in
520 sporadic PD patients and 520 healthy subjects.
Distributions of the rs3129882 (A/G) polymorphism in
both PD and healthy groups showed no evidence of
deviation from Hardy–Weinberg’s equilibrium. There
was no significant difference in gender and age distri-
butions between two groups (P > 0.05).
The allele and genotype frequencies of SNP
rs3129882 (A/G) in study groups are shown in
Table 1. Significant differences were found in allele
(P = 0.031) and genotype frequencies (P = 0.005)
between patients and controls. The association of the
SNP with PD risk was also significant under additive
and dominant models, where the A allele was observed
to be protective. The data are shown in Table 2.
Discussion
Parkinson’s disease is a complex neurodegenerative dis-
order classified as sporadic (90% cases) and familial
(10% cases) types (Chang et al., 2011; Dexter &
Jenner, 2013). Association studies, mainly GWAS, have
been widely used in an attempt to identify common
genetic variations that carry an increased risk to
develop the disease. They have discovered susceptibility
loci for PD (Satake et al., 2009; Simon-Sanchez et al.,
2009; Hamza et al., 2010; Do et al., 2011; Saad et al.,
2011; Lill et al., 2012; Pankratz et al., 2012). The
association of Human Leucocyte Antigen (HLA) with
PD was revealed in a GWAS carried out on Caucasian
population by Hamza et al. (2010). They indicated a
positive relationship between rs3129882 and the
increased risk of PD. It is assumed the intronic variant
plays a role as a cis-acting regulatory element, which
correlates significantly with the overexpression of DR
antigens in substantia nigra. The finding is not so far
beyond expectation because of the previous evidences
for involvement of neuroinflammation and adaptive
immunity in PD pathogenesis (Tansey et al., 2007;
Gagne & Power, 2010). Our study, in consistent
with Hamzah et al., showed a significant association
Table 1. Genotype and alleles frequencies of SNP rs3129882 in Parkinson’s disease (PD) and control groups
Subjects
Genotype frequencies (%)
P-value (v2)
Allele frequencies (%)
P-value (v2)G/G A/G A/A G A
PD 172 (33.07) 238 (45.76) 110 (21.15) 0.005* (10.35) 582 (55.97) 458 (44.03) 0.031* (4.64)
Control 127 (24.42) 281 (54.03) 112 (21.73) 533 (51.25) 507 (48.75)
*P value less than 0.05 considered as signiﬁcant.
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between mentioned SNP and the risk of PD. Moreover,
the higher frequency of A allele in controls suggesting a
protective role for this allele. Similarly, it can be postu-
lated that G allele plays as a susceptible factor for the
disease. Statistical analysis of genotypes reflecting the
GG genotype to be more frequent in patients compared
with healthy individuals suggesting the susceptible
nature of this genotype.
Our data are in parallel with several other studies
on different populations. A cohort study on Chinese
population showed a statistically significant relation-
ship between this variant and late-onset sporadic form
of PD (Guo et al., 2011). Puschmann et al. fail to find
any association; in a recessive model, they reported
the GG genotype to have a protective role in their
studied population (Puschmann et al., 2011). Simi-
larly, an original study followed by a meta-analysis of
four GWAS data set showed a lack of association
between rs3129882 and PD in French population, sug-
gested rs660895 located on HLA-DRB1 as a suscepti-
bility factor (Ahmed et al., 2012). This lack of
association also was observed in two independent
study on Dutch (Simon-Sanchez et al., 2011), Scandi-
navian (Pihlstrom et al., 2013; Ran et al., 2013) and
Taiwanese populations (Chiang et al., 2012; Lin et al.,
2013). Such discrepancies may be because of genetic
heterogeneity or sample size differences among various
studies. Technical differences in genotyping assay can
be another reason for such diversity. Our finding was
also supported by Zhao et al. who reported the pro-
tective role of A allele (Zhao et al., 2013). They
showed that this allelic effect transmits via a dominant
model (OR = 0.77, 95% CI = 0.62, 0.96, P = 0.018).
More specifically, it has been shown that this poly-
morphism is in relation with the late onset of disease
(P = 2.4 9 108) (Hamza et al., 2010). Based on a
hypothesis, that genetic architecture is different
between sporadic and familial PD cases, a recent study
reported that HLA rs3129882 was more strongly asso-
ciated with sporadic PD than familial PD (Hill-Burns
et al., 2014).
Data from Meta-analysis studies provide additional
source of comparison. Interestingly, it has been postu-
lated that there may be more than one PD associated
variant within the HLA region, so that haplotypes
including this alleles increases the risk of the disease
(Hill-Burns et al., 2011). Wissemann et al. put a step
forward suggesting that noncoding SNPs including
rs3129882 located in HLA region can be related to
the disease, regardless of HLA classes. They suggested
these SNPs to be in a first line of association before
the HLA associations, reflecting the involvement of
regulatory elements (Wissemann et al., 2013).
In conclusion, to the best of our knowledge, this is
the first study designed to assess the role of the
rs3129882 gene variants in a large replicated case–
control of Iranian patients with PD. We detected a
significant difference in both allelic and genotype fre-
quency in the Parkinson’s disease group compared
with the control group. These results suggest the
rs3129882 (A/G) polymorphism may be a risk factor
for PD in Iranian population. However, these data still
need to be validated in other populations.
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